hemospray

From Aaushi
Jump to navigation Jump to search

Indications

Contraindications

Mechanism of action

  • delivers a mineral powder to the bleeding site during GI endoscopy
  • when the powder contacts blood, it creates a gel that forms a stable mechanical barrier that covers the bleeding
  • stops bleeding within 5 minutes in 95% of cases
    • 20% experience rebleeding within 30 days (generally within 3 days)

Complications

More general terms

References

  1. FDA News Release. May 7, 2018 FDA permits marketing of new endoscopic device for treating gastrointestinal bleeding https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm606799.htm